BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab (Leqembi®), including four-year efficacy and safety data and data on the subcutaneous ...

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation ...

Loe said that while Fast Track status doesn’t guarantee PMN310 will succeed in future Phase II or III Alzheimer’s trials, it ...

Alzheimer’s disease is a type of dementia, and there are more than 7 million Americans living with it. According to the ...

Eisai has scaled down its sales expectations for Alzheimer's disease drug Leqembi after sluggish sales growth in the first half of the current fiscal year.

Health technology assessment (HTA) agency NICE said this morning that Eisai's Leqembi (lecanemab) and Lilly's Kisunla (donanemab) should not be provided through the NHS in England – and the ...

A new study has found that an experimental drug may delay the onset of Alzheimer’s-related dementia in people who are almost ...

Dr. Ausim Azizi is among those seeing the overall early results, as Yale New Haven Hospital is in the forefront of research ...

A growing number of studies have linked midlife mental health disturbances with the development of dementia, but it’s a ...

TOKYO, July 22, 2025 - (JCN Newswire) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced the termination of its engine business operation at Shenyang Aerospace Mitsubishi Motors ...